DK144261B - - Google Patents
Download PDFInfo
- Publication number
- DK144261B DK144261B DK280174AA DK280174A DK144261B DK 144261 B DK144261 B DK 144261B DK 280174A A DK280174A A DK 280174AA DK 280174 A DK280174 A DK 280174A DK 144261 B DK144261 B DK 144261B
- Authority
- DK
- Denmark
- Prior art keywords
- allopurinol
- tablet
- weight
- tablet according
- tablets
- Prior art date
Links
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 69
- 229960003459 allopurinol Drugs 0.000 claims description 67
- 239000008187 granular material Substances 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 19
- 239000003979 granulating agent Substances 0.000 claims description 14
- 239000007884 disintegrant Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 238000005469 granulation Methods 0.000 description 13
- 230000003179 granulation Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229920003110 Primojel Polymers 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 238000000227 grinding Methods 0.000 description 6
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 5
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229950002752 oxipurinol Drugs 0.000 description 4
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000010354 integration Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- -1 80-90% by weight Chemical compound 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- XGGAWFDOIDZRPI-UHFFFAOYSA-N 4,6-Dihydroxy Natural products C1=C2OCOC2=CC(C2OC(C3C(OC(O)C32)C=2C=C3OCOC3=CC=2)O)=C1 XGGAWFDOIDZRPI-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2462873A GB1460302A (en) | 1973-05-23 | 1973-05-23 | Tablet formulation |
| GB2462873 | 1973-05-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK144261B true DK144261B (enrdf_load_stackoverflow) | 1982-02-01 |
| DK144261C DK144261C (da) | 1991-02-04 |
Family
ID=10214700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK280174AA DK144261C (da) | 1973-05-23 | 1974-05-22 | Medicinsk tablet indeholdende allopurinol |
Country Status (21)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1533243A (en) * | 1975-02-13 | 1978-11-22 | Wellcome Found | Tablet formulation |
| US4143129A (en) | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
| US4115563A (en) * | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| DE3839825A1 (de) * | 1988-11-25 | 1990-06-13 | Henning Berlin Gmbh | Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze |
| WO1996002234A1 (es) * | 1994-07-18 | 1996-02-01 | Luis Cipriano Carvajal Martin | Granulos compactos altamente autodisgregantes para uso en formas galenicas conteniendo principios activos insolubles o poco solubles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB975850A (en) * | 1955-08-10 | 1964-11-18 | Wellcome Found | Xanthine oxidase inhibitors |
| US3624205A (en) * | 1967-04-25 | 1971-11-30 | Burroughs Wellcome Co | Treatment of hyperuricemia in humans |
-
1973
- 1973-05-23 GB GB2462873A patent/GB1460302A/en not_active Expired
-
1974
- 1974-05-22 HU HUWE507A patent/HU170656B/hu unknown
- 1974-05-22 IL IL44877A patent/IL44877A/en unknown
- 1974-05-22 ZA ZA00743318A patent/ZA743318B/xx unknown
- 1974-05-22 BE BE144636A patent/BE815409A/xx not_active IP Right Cessation
- 1974-05-22 AU AU69252/74A patent/AU469472B2/en not_active Expired
- 1974-05-22 JP JP5776774A patent/JPS577128B2/ja not_active Expired
- 1974-05-22 AT AT426774A patent/AT351167B/de not_active IP Right Cessation
- 1974-05-22 SE SE7406864A patent/SE402525C/sv not_active IP Right Cessation
- 1974-05-22 FR FR7417820A patent/FR2230341B1/fr not_active Expired
- 1974-05-22 CA CA200,536A patent/CA977279A/en not_active Expired
- 1974-05-22 DE DE19742424950 patent/DE2424950A1/de active Pending
- 1974-05-22 IE IE1097/74A patent/IE39283B1/xx unknown
- 1974-05-22 DK DK280174AA patent/DK144261C/da not_active IP Right Cessation
- 1974-05-22 NL NLAANVRAGE7406873,A patent/NL190436C/xx not_active IP Right Cessation
- 1974-05-22 FI FI1566/74A patent/FI156674A7/fi unknown
- 1974-05-23 CY CY941A patent/CY941A/xx unknown
- 1974-12-02 KE KE2808A patent/KE2808A/xx unknown
-
1978
- 1978-01-05 HK HK13/78A patent/HK1378A/xx unknown
- 1978-12-31 MY MY1978181A patent/MY7800181A/xx unknown
-
1980
- 1980-06-13 IT IT8048966A patent/IT8048966A0/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE402525C (sv) | 1982-11-22 |
| IL44877A (en) | 1976-11-30 |
| ATA426774A (de) | 1978-12-15 |
| IE39283L (en) | 1974-11-23 |
| IT8048966A0 (it) | 1980-06-13 |
| CA977279A (en) | 1975-11-04 |
| NL7406873A (enrdf_load_stackoverflow) | 1974-11-26 |
| AU6925274A (en) | 1975-11-27 |
| IE39283B1 (en) | 1978-09-13 |
| IL44877A0 (en) | 1974-07-31 |
| JPS577128B2 (enrdf_load_stackoverflow) | 1982-02-09 |
| FR2230341B1 (enrdf_load_stackoverflow) | 1977-04-15 |
| FR2230341A1 (enrdf_load_stackoverflow) | 1974-12-20 |
| HU170656B (enrdf_load_stackoverflow) | 1977-07-28 |
| NL190436B (nl) | 1993-10-01 |
| HK1378A (en) | 1978-01-13 |
| KE2808A (en) | 1978-02-17 |
| AT351167B (de) | 1979-07-10 |
| FI156674A7 (enrdf_load_stackoverflow) | 1974-11-24 |
| MY7800181A (en) | 1978-12-31 |
| BE815409A (fr) | 1974-11-22 |
| DK144261C (da) | 1991-02-04 |
| JPS5040721A (enrdf_load_stackoverflow) | 1975-04-14 |
| ZA743318B (en) | 1975-05-28 |
| SE402525B (sv) | 1978-07-10 |
| NL190436C (nl) | 1994-03-01 |
| GB1460302A (en) | 1977-01-06 |
| AU469472B2 (en) | 1976-02-12 |
| CY941A (en) | 1978-06-23 |
| DE2424950A1 (de) | 1974-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960009182B1 (ko) | 제약정제, 제약과립 및 그의 제조방법 | |
| EP0255404B1 (en) | Sustained release ibuprofen formulation | |
| CA2474674C (en) | Solid preparation containing single crystal form | |
| NO174876B (no) | Fremgangsmåte for fremstilling av et medikament i form av granuler basert på fenofibrat, innbefattende en inert kjerne | |
| EA029890B1 (ru) | Фармацевтическая композиция и фармацевтическая композиция в пероральной дозированной лекарственной форме на основе ингибитора dpp iv | |
| SE453797B (sv) | Terapeutisk, solid enhetsdoseringsform med forlengt utlosningsmonster vars berarmaterial innehaller hydroxypropylmetylcellulosa med hog molekyler vikt | |
| NO344367B1 (no) | Et fysisk og kjemisk stabilt nikotin-inneholdende partikkelformet materiale | |
| AU753482B2 (en) | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates | |
| NO175884B (no) | Fremgangsmåte for fremstilling av en presset tablett som inneholder methylprednisolon og et super-desintegrasjonsmiddel | |
| JP2011144194A (ja) | 医薬組成物 | |
| JP4636796B2 (ja) | ルミラコキシブ含有医薬組成物 | |
| NL8203343A (nl) | Farmaceutisch preparaat. | |
| Alhalmi et al. | Sustained release matrix system: an overview | |
| DK144261B (enrdf_load_stackoverflow) | ||
| AU2002213900A1 (en) | Pharmaceutical compositions | |
| FR2529784A1 (fr) | Medicament a liberation retardee contenant du 1-(p-(isopropylthio)-phenyl)-2-octylamino-1-propanol | |
| EP3345626A1 (en) | Super-rapid disintegrating tablet, and method for producing same | |
| CN105407876B (zh) | 抗结核病的稳定的包含异烟肼颗粒和利福喷汀颗粒的可分散的片剂及其制备方法 | |
| NO774400L (no) | Fremgangsmaate til fremstilling av farmasoeytiske sammensetninger | |
| DK143247B (da) | Medicinsk tablet indeholdende som aktiv bestanddel en 2,4-diamino-5-benzylpyrimidin sammen med et sulfonamid | |
| IE51157B1 (en) | Sustained release theophylline tablet having reduced bulk | |
| NO133220B (enrdf_load_stackoverflow) | ||
| US3642993A (en) | Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension | |
| RU2207116C1 (ru) | Лекарственное средство в виде таблеток на основе экстракта пустырника | |
| Kothawade et al. | Formulation and evaluation of sustained release matrix tablet of mefenamic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |